After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

It also has a follow-up ADC targeting c-Met in phase 1 clinical testing (ABBV-400), along with a candidate targeting CD19 (ABBV-319) for B-cell malignancies and another directed at SEZ6 (ABBV-706 ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the ...